Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-07

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Lipodystrophy is a health problem in which the body does not have enough fat tissue. People with lipodystrophy may not make enough of the hormone leptin. Leptin regulates hunger. Low leptin levels trigger hunger. People with lipodystrophy can have many health problems. They may take a drug (metreleptin) that mimics leptin. Little is known about how taking metreleptin may affect a pregnancy. Metreleptin may be helpful or harmful to pregnant women. It may also affect the health of the child who is born.

Objective:

This natural history study will collect data about the effects of taking metreleptin while pregnant.

Eligibility:

Women aged 18 years or older with lipodystrophy who have been pregnant. Women who did and who did not take metreleptin during their pregnancies are needed. Children of women with lipodystrophy who took this drug during pregnancy are also needed.

Design:

Participants will have 1 study visit. This visit may be by phone, by telehealth, or in-person.

Participants will answer questions about their pregnancies.

They will discuss any health problems they had.

They will be asked about any medicines they took before and during their pregnancies.

They will be asked about the health of their children.

Participants medical records will be reviewed.

Participants may need to provide a blood sample. They may also be asked to provide a sample of breastmilk.

Participants children may also be asked to provide a blood sample....

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Leptin and Cytokines in Diabetic Pregnancy - Physiologic or Pathogenic Role

NCT00334841

Gestational Diabetes Mellitus Preeclampsia Placental Hypoxia

UNKNOWN

Role of Liver and Visceral Fat in Glucose and Lipid Metabolism During Pregnancy

NCT02282475

Pregnancy Gestational Diabetes Obesity +1 more

COMPLETED

Longitudinal Measures of Leptin in Pregnant Women Who Developed Preeclampsia

NCT01649167

High-Risk Pregnancy

COMPLETED

A Low Glycemic Load Diet During Pregnancy in Overweight Women

NCT00364403

Overweight Pregnancy

COMPLETED NA

Regulation Of Maternal Fuel Supply And Neonatal Adiposity

NCT00826904

Fetal Macrosomia Gestational Diabetes

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Description:

Single-site cross-sectional study of women with lipodystrophy who had pregnancies during which they were or were not exposed to metreleptin, and the offspring of women whose offspring were exposed to metreleptin during pregnancy. The study involves secondary use of data and samples from other studies in which these subjects participated, review of outside medical records, and collection of a single blood specimen if a biobanked specimen is not available.

The hypotheses are:

1. Pregnancy complications will be less prevalent and severe in women with lipodystrophy who took metreleptin during pregnancy compared to those who did not, due the beneficial effects of metreleptin on metabolic complications of lipodystrophy.
2. Anti-leptin antibodies may be detected in some offspring born to women with lipodystrophy treated with metreleptin during pregnancy, but these antibodies will not be associated with adverse health outcomes.

Objectives:

Primary: Determine pregnancy outcomes, including type and frequency of pregnancy complications in women treated with metreleptin during pregnancy vs. untreated pregnancies.

Secondary: Determine if anti-leptin antibodies are detectable in offspring of women treated with metreleptin during pregnancy.

Endpoints:

Primary Endpoint: We will quantify a set of pregnancy and offspring outcomes and complications.

Secondary Endpoints: Frequency and type of anti-leptin antibodies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lipodystrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

off-spring of above

Off-spring of the women who took metreleptin during her pregnancy.

No interventions assigned to this group

Women with past pregnancy on metreleptin

Women who took metreleptin during pregnancy.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

* Women with lipodystrophy who had pregnancies with or without use of metreleptin:

* Female, aged \>= 18 years
* Clinical diagnosis of non-HIV associated generalized or partial lipodystrophy
* History of one or more pregnancies
* Offspring of women with lipodystrophy who had pregnancies while taking metreleptin:

* Males or females aged \>=1 month
* Mothers took metreleptin during their pregnancy
* Availability of a biobanked blood specimen or willingness to provide a blood specimen

Note that subjects treated with metreleptin during pregnancy may participate in this study regardless of the participation of their offspring.

Exclusion Criteria

In order to be eligible to participate in this study, an individual must not meet any of the following criteria:

* Inability of subject or guardian to understand or the unwillingness to sign a written informed consent document (except as noted below with \*)
* Pregnancy.

Minimum Eligible Age

6 Months

Maximum Eligible Age

98 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No